id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2005-E-0311-0007,FDA,FDA-2005-E-0311,"Certificate Extending Patent Term from U.S. Patent and Trademark Office to OSI Pharmaceuticals, Inc.",Rule,Certificate Extending Patent Term,2007-10-17T04:00:00Z,2007,10,,,2025-12-03T10:00:20Z,,0,0,0900006480447827
FDA-2005-E-0311-0006,FDA,FDA-2005-E-0311,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2007-05-14T04:00:00Z,2007,5,,,2025-12-03T00:36:31Z,,0,0,090000648044781e
FDA-2005-E-0311-0005,FDA,FDA-2005-E-0311,Determination of Regulatory Review Period for Purposes of Patent Extension; TARCEVA,Notice,General Notice,2006-09-29T04:00:00Z,2006,9,2006-09-29T04:00:00Z,,2025-12-03T00:32:04Z,E6-15987,0,0,090000648044781c
FDA-2005-E-0311-0004,FDA,FDA-2005-E-0311,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2006-09-11T04:00:00Z,2006,9,,,2025-12-03T00:28:49Z,,0,0,0900006480447819
FDA-2005-E-0311-0003,FDA,FDA-2005-E-0311,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2005-07-18T04:00:00Z,2005,7,,,2025-12-03T00:14:12Z,,0,0,0900006480447816
FDA-2005-E-0311-0002,FDA,FDA-2005-E-0311,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2005-07-15T04:00:00Z,2005,7,,,2025-12-03T00:12:38Z,,0,0,0900006480447814
FDA-2005-E-0311-0001,FDA,FDA-2005-E-0311,Letter from U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2005-06-22T04:00:00Z,2005,6,,,2025-12-03T00:10:21Z,,0,0,09000064804477c9